NEW YORK, Feb 21 – Aclara Biosciences said Wednesday its fourth-quarter 2000 revenues slipped to $733,000, from $855,000 a year ago, as declining revenues from a drug screening offset revenue increases from government grants and a collaboration with Cellomics.

For 2000, revenues were up 21 percent to $3.5 million, mostly as a result of the Cellomics partnership.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.